Eastman Kodak has entered into OEM deals with ISG Technologiesand Applicare Medical Imaging, continuing the Rochester, NY, company'strend toward outsourcing PACS components.In the Applicare deal, Kodak has accessed the Dutch PACS firm'sRadWorks PC-based
Eastman Kodak has entered into OEM deals with ISG Technologiesand Applicare Medical Imaging, continuing the Rochester, NY, company'strend toward outsourcing PACS components.
In the Applicare deal, Kodak has accessed the Dutch PACS firm'sRadWorks PC-based teleradiology software for marketing in 15 countriesin Europe, Africa, and the Middle East. RadWorks is a WindowsNT-based product that can be linked to Kodak's Digital Sciencemedical image management software. Kodak's Australian subsidiaryalso received rights to market RadWorks in Australia and New Zealand,alongside Applicare's existing distributor in the region, OxfordScientific.
Details on the agreement with ISG of Mississauga, Ontario, aresketchy, but ISG president Thomas Cafarella confirmed that hiscompany has entered a deal with Kodak Health Imaging divisionin Richardson, TX, to supply Kodak with distributed viewing softwarefor use in PACS applications. Kodak signed a deal with ISG competitorCemax-Icon earlier this year (SCAN 2/28/96).
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.